Apogee Therapeutics (APGE) CEO exercises options, holds 1.14M shares

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock at $22.86 per share. Following this exercise, he directly holds 1,135,987 shares of common stock.

The exercised options are part of a grant representing the right to purchase 398,512 shares, which vests in forty-eight equal monthly installments over four years, subject to his continued service. After this transaction, 387,012 options from this grant remain outstanding and are scheduled to expire on December 18, 2033.

Insider Trade Summary

3,000 shares exercised/converted

Mixed 2 txns

Insider HENDERSON MICHAEL THOMAS

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	--
Exercise	Common Stock	3,000	$22.86	$69K

Holdings After Transaction: Stock Option (Right to Buy) — 387,012 shares (Direct, null); Common Stock — 1,135,987 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options exercised: 3,000 shares Exercise price: $22.86 per share Common shares held after: 1,135,987 shares +3 more

6 metrics

Options exercised 3,000 shares Common stock acquired via option exercise on 2026-04-16

Exercise price $22.86 per share Exercise or conversion price for 3,000 options

Common shares held after 1,135,987 shares Total direct common stock ownership after transaction

Total option grant size 398,512 shares Right to purchase common stock under reported option grant

Remaining options after exercise 387,012 options Stock options still outstanding following 3,000-share exercise

Option expiration date December 18, 2033 Expiry of reported stock option grant

Key Terms

Stock Option (Right to Buy), vest in forty-eight equal monthly installments, continued service

3 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for derivative transaction"

vest in forty-eight equal monthly installments financial

""which will vest in forty-eight equal monthly installments over a four-year period""

continued service financial

""subject to the Reporting Person's continued service to the Issuer""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/16/2026		M		3,000	A	$22.86	1,135,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.86	04/16/2026		M			3,000	(1)	12/18/2033	Common Stock	3,000	$0.00	387,012	D

Explanation of Responses:

1. This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Michael Henderson	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for its CEO?

Apogee Therapeutics CEO Michael Thomas Henderson exercised stock options to acquire 3,000 shares of common stock. The options were exercised at a price of $22.86 per share, increasing his direct holdings to 1,135,987 shares after the transaction.

How many Apogee (APGE) shares does the CEO hold after this Form 4?

After the reported option exercise, CEO Michael Thomas Henderson directly holds 1,135,987 shares of Apogee Therapeutics common stock. This total reflects his position following the acquisition of 3,000 shares through the exercise of stock options at $22.86 per share.

At what price did the Apogee (APGE) CEO exercise his stock options?

The CEO exercised stock options at an exercise price of $22.86 per share for 3,000 shares of Apogee Therapeutics common stock. This price represents the fixed conversion or exercise price specified in the underlying option grant reported in the filing.

What is the size and vesting schedule of the CEO’s Apogee (APGE) option grant?

The option grant represents the right to purchase 398,512 Apogee Therapeutics common shares. It vests in forty-eight equal monthly installments over four years from the grant date, subject to Michael Thomas Henderson’s continued service with the company during the vesting period.

How many stock options remain outstanding for the Apogee (APGE) CEO after this exercise?

Following the exercise of 3,000 options, 387,012 stock options from this grant remain outstanding for CEO Michael Thomas Henderson. These remaining options continue to be tied to Apogee Therapeutics common stock and are scheduled to expire on December 18, 2033.

When do the CEO’s Apogee (APGE) stock options expire?

The stock options reported in the Form 4 for Apogee Therapeutics CEO Michael Thomas Henderson are scheduled to expire on December 18, 2033. This expiration date applies to the remaining 387,012 options from the original 398,512-share grant.